

Sara Lonardi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6029379/sara-lonardi-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260 papers	11,685 citations	45 h-index	102 g-index
284 ext. papers	15,293 ext. citations	5.8 avg, IF	5.8 L-index

#	Paper	IF	Citations
260	An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.. <i>Current Oncology</i> , 2022 , 29, 544-550	2.8	1
259	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , 2022 , 27, e29-e36	5.7	0
258	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. 2022 , 10,		2
257	Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology.. <i>Patient Preference and Adherence</i> , 2022 , 16, 353-362	2.4	0
256	Interaction via Wnt/B-Catenin Is Associated with Patients' Survival in HER2-Positive Metastatic Gastric Adenocarcinoma.. <i>Cancers</i> , 2022 , 14,	6.6	1
255	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102583	2.2	4
254	BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103647	7	0
253	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.. <i>European Journal of Cancer</i> , 2022 , 167, 81-91	7.5	0
252	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. <i>European Journal of Cancer</i> , 2022 , 167, 23-31	7.5	0
251	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.. <i>European Journal of Cancer</i> , 2022 , 166, 165-175	7.5	1
250	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGE0-GONO case series.. <i>European Journal of Cancer</i> , 2022 , 168, 34-40	7.5	0
249	Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.. <i>JCO Precision Oncology</i> , 2022 , 6, e2200037	3.6	0
248	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-14	7.1	0
247	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022 , 170, 64-72	7.5	0
246	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. <i>Cancers</i> , 2022 , 14, 2568	6.6	0
245	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.. <i>European Journal of Cancer</i> , 2021 , 161, 90-98	7.5	3
244	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.. <i>Cancer Management and Research</i> , 2021 , 13, 9379-9389	3.6	2

243	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102008	2.2	7
242	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study 2021 , 9,		3
241	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101015	2.2	29
240	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	4
239	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021 , 9,	4.8	2
238	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2021 , 39, 1108-1118	2.2	20
237	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		5
236	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021 , 16, 517-527	5	1
235	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. <i>European Journal of Cancer</i> , 2021 , 148, 190-201	7.5	0
234	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021 , 13,	6.6	7
233	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 150, 155-167	7.5	15
232	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021 , 23, 915-920	3.8	4
231	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	9
230	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021 , 125, 839-845	8.7	2
229	Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. <i>Tumori</i> , 2021 , 107, 46-54	1.7	2
228	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021 , 124, 183-190	8.7	5
227	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021 , 39, 966-977	2.2	42
226	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021 , 26, 302-309	5.7	4

225	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 144, 31-40	7.5	5
224	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021 , 29, 3971-3980	3.9	3
223	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy: Two-year clinical update.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 58-58	2.2	6
222	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 631-641	2.2	17
221	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021 , 41, 1389-1397	7.9	14
220	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. <i>Medical Oncology</i> , 2021 , 38, 17	3.7	
219	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021 , 21, 285-295	3.5	0
218	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021 , 39, 642-651	2.2	27
217	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2505-2514	12.9	3
216	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154	7.5	6
215	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		2
214	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021 , 153, 16-26	7.5	1
213	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021 , 155, 73-84	7.5	3
212	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
211	Genetic Variants of the Gene, Telomere Length, and Circulating as Prognostic Markers in Rectal Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	2
210	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020 , 25, 803-809	5.7	17
209	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020 , 123, 403-409	8.7	22
208	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 4485-4493	12.9	9

207	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020 , 15, e0232449	3.7	23
206	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. <i>Gastric Cancer</i> , 2020 , 23, 1064-1074	7.6	4
205	Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. <i>JAMA Oncology</i> , 2020 , 6, 927-929	13.4	9
204	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020 , 12,	6.6	4
203	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4661-4669	12.9	7
202	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020 , 147, 3177-3188	7.5	9
201	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020 , 135, 78-88	7.5	5
200	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020 , 99, e19958	1.8	9
199	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 219-225	3.8	16
198	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 497-507	21.7	98
197	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 256-262.e2	3.8	22
196	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
195	Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. <i>BMC Cancer</i> , 2020 , 20, 633	4.8	12
194	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020 , 135, 230-239	7.5	6
193	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919899850	5.4	1
192	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020 , 25, 481-487	5.7	43
191	The heterogeneous clinical and pathological landscapes of metastatic -mutated colorectal cancer. <i>Cancer Cell International</i> , 2020 , 20, 30	6.4	22
190	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020 , 130, 63-71	7.5	7

189	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1017-1024	12.9	8
188	Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11-11	2.2	30
187	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020 , 133, 66-73	7.5	4
186	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 493-501	4.9	5
185	PD-L1 expression in gastroesophageal dysplastic lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 151-156	5.1	10
184	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020 , 15, e0239439	3.7	3
183	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020 , 139, 81-89	7.5	3
182	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020 , 5, e000911	6	35
181	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 773-785	5	8
180	AtezotRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020 , 20, 683	4.8	26
179	Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. <i>Cancers</i> , 2020 , 12,	6.6	3
178	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020 , 147, 2303-2315	7.5	7
177	Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 547-551	13.4	17
176	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101889	14.4	39
175	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , 2019 , 9, 11527	4.9	9
174	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 121, 593-599	8.7	14
173	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3099-3110	2.2	35
172	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 269-279.e5	3.8	3

171	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 1632-1643	59.2	481
170	Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 637-642	3.6	6
169	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 420-435	21.7	110
168	Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). <i>Cancer Management and Research</i> , 2019 , 11, 3631-3642	3.6	15
167	An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 635-644	3.8	2
166	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. <i>British Journal of Cancer</i> , 2019 , 121, 257-263	8.7	20
165	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019 , 111, 94-106	7.5	25
164	Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. <i>Tumori</i> , 2019 , 105, 243-252	1.7	1
163	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019 , 25, 3954-3961	12.9	36
162	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019 , 105, 353-358	1.7	3
161	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019 , 4, e000489	6	8
160	Ramucirumab: the long and winding road toward being an option for mCRC treatment. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 399-409	5.4	3
159	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019 , 19, 283	4.8	8
158	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019 , 109, 175-182	7.5	17
157	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019 , 110, 32-41	7.5	12
156	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 125-132.e2	3.8	23
155	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients' Prognosis. <i>International Journal of Surgical Pathology</i> , 2019 , 27, 816-835	1.2	4
154	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29

153	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. <i>Digestive and Liver Disease</i> , 2019 , 51, 1713-1719	3.3	11
152	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019 , 9, 622	5.3	17
151	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
150	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. <i>Annals of Oncology</i> , 2019 , 30, 1466-1471	10.3	53
149	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status 2019 , 7, 297		10
148	Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 202-202	2.2	2
147	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 635-635	2.2	22
146	Immune senescence and immune activation in elderly colorectal cancer patients. <i>Aging</i> , 2019 , 11, 3864-3875	3.75	6
145	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. <i>World Journal of Gastroenterology</i> , 2019 , 25, 5773-5788	5.6	45
144	Another Chapter of the : Is Primary Tumor Location a Prognostic Feature in Mutant Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2019 , 24, e77-e79	5.7	3
143	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019 , 24, 1395-1402	5.7	45
142	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019 , 24, 385-393	5.7	15
141	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. <i>Translational Oncology</i> , 2019 , 12, 282-291	4.9	10
140	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 343-350	13.4	134
139	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019 , 42, 159-179	5.1	13
138	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019 , 42, 211-233	5.1	40
137	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. <i>Annals of Oncology</i> , 2019 , 30, 124-131	10.3	29
136	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. <i>British Journal of Cancer</i> , 2018 , 118, 878-886	8.7	12

135	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018 , 36, 709-714	4.3	5
134	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018 , 29, 1528-1534	10.3	58
133	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018 , 12, 33-37	4.5	2
132	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 529-536	13.4	51
131	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 251-266	3.5	29
130	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018 , 29, 924-930	10.3	60
129	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018 , 13, 227-234	5	23
128	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e395-e414	3.8	16
127	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018 , 118, 955-965	8.7	10
126	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. <i>Acta Oncologica</i> , 2018 , 57, 412-419	3.2	0
125	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018 , 18, 623-632	3.5	4
124	Association of -3 rs1053004 and rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018 , 9, 367	5.6	11
123	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 34, 148-162.e7	24.3	77
122	Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. <i>Annals of Oncology</i> , 2018 , 29, 1955-1963	10.3	31
121	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000403	6	15
120	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 98	4.8	6
119	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e601-e615	3.8	8
118	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018 , 13, e0193640	3.7	3

117	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 7859-7866	3.3	18
116	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1478-1485	2.2	41
115	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 773-779	2.2	938
114	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. <i>Cancer Cell International</i> , 2018 , 18, 131	6.4	6
113	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018 , 23, 1178-1187	5.7	31
112	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. <i>Pharmacogenomics</i> , 2017 , 18, 197-200	2.6	7
111	An untreatable dyspnoea: more defendants under investigation. <i>Internal and Emergency Medicine</i> , 2017 , 12, 199-205	3.7	
110	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017 , 77, 13-20	7.5	15
109	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 1495-1502	2.4	30
108	Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. <i>British Journal of Cancer</i> , 2017 , 117, 1269-1277	8.7	34
107	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiALldh) trial. <i>British Journal of Cancer</i> , 2017 , 117, 1099-1104	8.7	10
106	QoL is a cool tool. <i>Annals of Oncology</i> , 2017 , 28, 2032-2033	10.3	2
105	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. <i>Histopathology</i> , 2017 , 71, 1008-1011	7.3	8
104	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2017 , 18, 1182-1191	21.7	1317
103	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017 , 83, 106-115	7.5	21
102	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 599-608	3.5	12
101	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1297-1308	5.4	17
100	Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study. <i>Techniques in Coloproctology</i> , 2017 , 21, 633-640	2.9	18

99	New perspectives for TAS-102: TASK successful?. <i>Lancet Oncology, The</i> , 2017 , 18, 1139-1141	21.7	1
98	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241	6	6
97	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24	7.5	28
96	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408	4.8	20
95	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2414-2422	12.9	111
94	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32
93	Immunotherapy in Gastrointestinal Cancers. <i>BioMed Research International</i> , 2017 , 2017, 4346576	3	45
92	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3531-3531	2.2	24
91	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 519-519	2.2	42
90	Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. <i>Annals of Oncology</i> , 2016 , 27, 2074-2081	10.3	33
89	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , 2016 , 27, 2082-2090	10.3	40
88	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94	5.7	72
87	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016 , 21, 600-7	5.7	20
86	gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study. <i>Annals of Oncology</i> , 2016 , 27, vi559	10.3	5
85	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1069-77	4.9	38
84	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. <i>Digestive and Liver Disease</i> , 2016 , 48, 231-41	3.3	60
83	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016 , 27, 843-9	10.3	36
82	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial 2016 ,		3

81	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS774-TPS774	2.2	16
80	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , 2016 , 7, 19781-193	3.3	11
79	In Reply. <i>Oncologist</i> , 2016 , 21, e5-e6	5.7	
78	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	10
77	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 877-85	3.8	10
76	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 738-746	21.7	533
75	Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: a first insight. <i>International Journal of Immunogenetics</i> , 2016 , 43, 32-9	2.3	14
74	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. <i>World Journal of Surgery</i> , 2015 , 39, 2500-9	3.3	14
73	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7	10.3	110
72	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2015 , 16, 499-508	21.7	568
71	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015 , 112, 1921-8	8.7	111
70	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015 , 26, 1188-1194	10.3	112
69	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015 , 20, 1261-5	5.7	29
68	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015 , 28, 1481-91	9.8	144
67	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology, The</i> , 2015 , 16, 1306-15	21.7	593
66	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 315-21	5.3	24
65	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 2503	10.3	15
64	MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. <i>Pharmacogenomics Journal</i> , 2015 , 15, 219-25	3.5	16

63	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015 , 20, 15-23	4.7	28
62	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 156	12.8	40
61	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015 , 137, 2971-80	7.5	48
60	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3508-3508	2.2	23
59	HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , 2015 , 10, e0144000	3.7	22
58	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 392-8	5.5	91
57	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014 , 110, 2165-9	8.7	56
56	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014 , 50, 57-63	7.5	136
55	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1609-18	59.2	663
54	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 862-73	21.7	190
53	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , 2014 , 4, 6828	4.9	29
52	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. <i>British Journal of Cancer</i> , 2014 , 111, 25-32	8.7	37
51	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , 2014 , 25, 2443-2444	10.3	2
50	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , 2014 , 25, 2378-2385	10.3	72
49	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. <i>Pharmacogenomics Journal</i> , 2013 , 13, 403-9	3.5	57
48	Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. <i>European Journal of Neurology</i> , 2013 , 20, 188-92	6	21
47	Immune senescence and cancer in elderly patients: results from an exploratory study. <i>Experimental Gerontology</i> , 2013 , 48, 1436-42	4.5	31
46	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013 , 24, 2062-7	10.3	74

45	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. <i>Cancer</i> , 2013 , 119, 3570-7	6.4	69
44	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. <i>European Journal of Neurology</i> , 2013 , 20, 788-94	6	24
43	Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. <i>British Journal of Cancer</i> , 2013 , 108, 278-84	8.7	51
42	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , 2013 , 8, e66774	3.7	55
41	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3648-TPS3648	2.2	7
40	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 336-336	2.2	20
39	Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. <i>Tumori</i> , 2013 , 99, 596-600	1.7	2
38	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32	6.4	32
37	Hepatoid adenocarcinoma of the colon: what should we target?. <i>Pathology and Oncology Research</i> , 2012 , 18, 93-6	2.6	20
36	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 3116-3122	10.3	56
35	Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3089-96	3.1	54
34	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 899-902	3.5	29
33	Significance of pulmonary nodules in patients with colorectal cancer. <i>European Radiology</i> , 2012 , 22, 1680-6	8.6	13
32	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 38-48	7	23
31	Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2461-8	3.1	87
30	Cancer in the elderly. <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 115-8	3.7	4
29	Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2773-80	2.2	597
28	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. <i>Annals of Oncology</i> , 2011 , 22, 1236-1242	10.3	85

27	Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. <i>Supportive Care in Cancer</i> , 2010 , 18, 601-8	3.9	43
26	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , 2010 , 51, 165-73	11.2	75
25	Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: a single-institution experience after a median follow-up of 95 months. <i>Annals of Surgical Oncology</i> , 2009 , 16, 893-9	3.1	25
24	Chemotherapy for operable and advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2009 , 35, 509-16	4.4	15
23	Adjuvant systemic chemotherapy with 5-fluorouracil and leucovorin in colon cancer: a monoinstitutional institutional experience. <i>Immunopharmacology and Immunotoxicology</i> , 2008 , 30, 235-42	3.2	2
22	Treatment of advanced breast cancer in elderly women: medical approach. <i>Aging Health</i> , 2008 , 4, 267-277		
21	Colon cancer in elderly patients: what is the best treatment?. <i>Aging Health</i> , 2008 , 4, 279-286		
20	Multidisciplinary management is strongly suggested in elderly patients with rectal carcinoma. <i>Aging Health</i> , 2008 , 4, 287-298		
19	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>British Journal of Cancer</i> , 2007 , 96, 1047-51	8.7	156
18	Multidisciplinary treatment of rectal cancer: medical oncology. <i>Annals of Oncology</i> , 2007 , 18 Suppl 9, ix114-21	10.3	5
17	Multidisciplinary treatment of rectal cancer: medical oncology. <i>Annals of Oncology</i> , 2007 , 18, 1908-15	10.3	9
16	Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 602-3; author reply 603	2.2	9
15	Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study. <i>Annals of Oncology</i> , 2007 , 18, 58-63	10.3	15
14	Oral anticancer drugs in the elderly: an overview. <i>Drugs and Aging</i> , 2007 , 24, 395-410	4.7	22
13	5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. <i>Archives of Medical Research</i> , 2006 , 37, 860-5	6.6	10
12	Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4668-9; author reply 4669	2.2	
11	Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. <i>European Journal of Surgical Oncology</i> , 2006 , 32, 1201-8	3.6	31
10	A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2005 , 16, 1140-6	10.3	118

9	Adjuvant chemotherapy in the treatment of high grade gliomas. <i>Cancer Treatment Reviews</i> , 2005 , 31, 79-89	14.4	51
8	Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3758-65	2.2	20
7	Chemotherapy in brain metastases of lung and breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 101-110		
6	Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. <i>Annals of Oncology</i> , 2003 , 14, 1727-31	10.3	27
5	Is intra-arterial chemotherapy useful in high-grade gliomas?. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 507-19	3.5	12
4	Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. <i>Annals of Oncology</i> , 2002 , 13, 1882-92	10.3	31
3	Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2002 , 28, 27-47	14.4	79
2	Phase II Single-Agent Studies in Elderly Cancer Patients. <i>Tumori</i> , 2002 , 88, S13-S14	1.7	2
1	Phase II single-agent studies in elderly cancer patients. <i>Tumori</i> , 2002 , 88, S13-4	1.7	2